Stockscreener 앱 받기
4.71
6.32%
0.28
전일 마감가:
$4.43
열려 있는:
$4.49
하루 거래량:
3.02M
Relative Volume:
1.97
시가총액:
$590.87M
수익:
$50.27M
순이익/손실:
$-68.91M
주가수익비율:
-7.8109
EPS:
-0.603
순현금흐름:
$-44.32M
1주 성능:
+11.88%
1개월 성능:
+13.91%
6개월 성능:
-18.93%
1년 성능:
+38.53%
1일 변동 폭
$4.445
$4.7399
1주일 범위
$4.125
$4.7399
52주 변동 폭
$2.93
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
명칭
Aquestive Therapeutics Inc
전화
908-941-1900
주소
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.71 | 590.87M | 50.27M | -68.91M | -44.32M | -0.603 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2019-04-22 | 개시 | H.C. Wainwright | Buy |
| 2019-01-03 | 개시 | Lake Street | Buy |
| 2018-08-20 | 개시 | JMP Securities | Mkt Outperform |
| 2018-08-20 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect - ACCESS Newswire
Aquestive Therapeutics (NYSE:AQST): What Insider Activity Reveals About Corporate Confidence - Kalkine Media
Have Aquestive Therapeutics Insiders Been Selling Stock? - simplywall.st
Aquestive Therapeutics Inc (AQST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aquestive Therapeutics Inc (AQST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aquestive Therapeutics Inc (AQST) Institutional Confidence - TradingKey
Aquestive Therapeutics Inc (AQST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aquestive Therapeutics Inc (AQST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aquestive Therapeutics Inc (AQST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aquestive Therapeutics Inc (AQST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aquestive Therapeutics CEO sells $104,010 in company stock By Investing.com - Investing.com Canada
Aquestive Therapeutics CEO sells $104,010 in company stock - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-06-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Krop Julie - Moomoo
Aquestive (AQST) awards Abigail Jenkins 50,500 stock options at $3.99 - Stock Titan
Aquestive Therapeutics (AQST) director receives 50,500 stock options grant - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
AQST: FDA progress, global expansion, and all proposals passed with strong shareholder support - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gew - The National Law Review
AQUESTIVE THERAPEUTICS INC (AQST) Stock Chart - ChartMill
Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire
2026-06-04 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics Q1 earnings call highlights - MSN
AQST: Aquestive TherapeuticsInteractive Chart - Zacks Investment Research
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review
2026-06-02 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics Charts Cautious, Liquid Path Forward - TipRanks
Aquestive Therapeutics CEO sells $35,413 in company stock By Investing.com - Investing.com South Africa
Aquestive Therapeutics CEO sells $35,413 in company stock - Investing.com UK
PRN_FinancialWrapper - FinancialContent
Aquestive secures $150 million debt facility with Oaktree By Investing.com - Investing.com Nigeria
Aquestive targets Q3 FDA resubmission for Anaphylm and projects >$150M cash at launch - MSN
A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $6 to $9 - Moomoo
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
All News about Aquestive Therapeutics, Inc.Common Stock - The Chronicle-Journal
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Aquestive Says It’s on Track to Launch Anaphylm Studies for FDA - Allergic Living
Analysts Have Made A Financial Statement On Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) First-Quarter Report - Moomoo
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2026 Earnings Call Transcript - Insider Monkey
Aquestive Therapeutics Inc (AQST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
11.23%
0.45%
자본화:
|
볼륨(24시간):